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A B S T R A C T   
Background: Asthma, a chronic inflammatory airway disease, shares common pathophysiological mechanisms 
with ischemic stroke. The aim of the study is to assess the association between asthma, levels of asthma control 
and ischemic stroke risk in men and women and by smoking habits. 
Methods: This prospective population-based cohort study utilized data on 58 712 adults from HUNT Study in 
Norway free from stroke. Self-reported asthma was categorized as ever asthma, non-active asthma and active 
asthma (i.e., being on asthma medication within 12 months of the baseline). Asthma control was defined ac-
cording to the Global Initiative for Asthma questionnaire and was categorized into controlled and not controlled 
asthma. Stroke was ascertained by linking HUNT data with Nord-Trøndelag hospital records and the Norwegian 
Patient Registry. 
Results: During a mean follow-up of 17.3 � 5.3 years, 2619 participants (4.5%) had a first stroke. Not controlled 
asthma was associated with a modest increased risk of stroke (adjusted HR 1.34, 95%CI 1.03–1.73). Subgroup 
analyses revealed that the respective association was stronger among those with history of smoking (HR 1.48, 
95%CI 1.10–2.00) and males (HR 1.55, 95%CI 1.12–2.16) while absent in non-smokers (HR 1.02, 95%CI 
0.61–1.70) and females (HR 1.05, 95%CI 0.69–1.60). Likewise, active asthma was associated with similar 
increased stroke risk among smokers and males and absent in non-smokers and females. 
Conclusions: Symptomatic and active asthma was associated with a modest increased relative risk for ischemic 
stroke in smokers and males. Future studies should clarify the difference in risks and mechanisms between 
different phenotypes of asthma.   
1. Introduction 
Stroke is the second leading cause of death globally and the leading 
cause of long-term and preventable disability [1]. Major risk factors such 
as smoking, hypertension and ageing population have been identified 
[1]. However, the burden of stroke is projected to rise and further un-
derstanding of risk factors of the disease is highly warranted. 
Asthma is a chronic inflammatory airway disease, characterized by 
reversible airway obstruction, affecting as many as 30 million in-
dividuals in Europe [2]. Asthma is not curable, but rather managed by 
controlling the symptoms, with asthma medication as a first line 
approach [3]. However, beta2-agonist use has been shown to increase 
the risk of arrythmias [4,5], a major risk factor for stroke [6]. Further-
more, asthma and atherosclerosis share many common risk factors and 
pathophysiologic pathways linked to the chronic inflammatory response 
present in both diseases [7]. The presence of asthma is associated with 
prothrombotic factors and endothelial dysfunction that contribute to the 
development of atherothrombosis [8,9]. Also, smoking is a major risk 
factor for both stroke and lung disease [10,11], and smokers with 
asthma are known to have poorer symptom control and disease prog-
nosis than non-smokers [12]. 
Several epidemiological studies have found a higher risk of stroke in 
adults with asthma compared to those without asthma [13–18]. How-
ever, most of previous studies could not distinguish between adult or 
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child-onset asthma and did not address the possibility of misclassifica-
tion between asthma and other lung diseases like COPD. In addition, no 
previous studies have assessed the association between levels of asthma 
control and stroke risk. Therefore, we used a large Norwegian popula-
tion cohort to assess the associations between asthma, asthma control 
and stroke risk in men and women and by smoking habits. 
2. Methods 
2.1. Study design and population 
All adults �20 years residing in Nord-Trøndelag County, Norway, 
received a postal invitation to participate in the HUNT Study. The HUNT 
study started in 1984–1986 and consists of four surveys, HUNT1 
(1984–86), HUNT2 (1995–97), HUNT3 (2006–08) and HUNT4 
(2017–2019). Information was collected by self-administered ques-
tionnaires and a clinical examination, which included blood sampling. A 
detailed description of HUNT can be found elsewhere [19,20]. 
We used data from HUNT2 and HUNT3, as information on asthma 
was not collected in HUNT1. A total of 65 229 (69.0% of those invited) 
and 50 807 individuals (54.1%) participated in HUNT2 and HUNT3, 
respectively, giving us a total sample of 78 964 individuals. Of the total 
sample, 28 160 individuals (35.7%) participated only in HUNT2, 37 069 
individuals (46.9%) participated in both HUNT2 and HUNT3 and 13 735 
individuals (17.4%) participated only in HUNT3. Of the 78 964 in-
dividuals, 23 726 (30.0%) were invited to HUNT Lung Study consisting 
of a random HUNT2 and HUNT3 sample and a symptom sample that 
included participants who reported attacks of wheezing or breathless-
ness during the last 12 months, a history of asthma or to ever have used 
asthma medication at baseline (Fig. S1). Of the invitees, 16 115 in-
dividuals (67.9%) participated completing additional interviews and 
questionnaires about asthma history, asthma symptoms, medication use 
and lung function [19] (Fig. 1). 
We excluded participants with missing information on asthma (n ¼
93 [0.1%]) or those with missing information on at least one covariate 
(total n ¼ 18 005 [22.8%]) with the following variables: physical ac-
tivity n ¼ 13 941 [17.7%], smoking status n ¼ 1702 [2.2%], alcohol use 
n ¼ 2678 [3.4%], education n ¼ 4540 [5.8%], diabetes n ¼ 124 
[0.16%], BMI n ¼ 919 [1.2%] and TotalC/HDL n ¼ 953 [1.3%]. In 
addition, to minimize potential undiagnosed asthma, we excluded those 
Fig. 1. Flowchart of the participants 
1 Based on asthma symptoms and medication use Asthma control based on the GINA Global Strategy for Asthma Management and Prevention guidelines. 
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who did not report asthma but had a history of taking medications 
prescribed for their asthma at baseline (n ¼ 485 [0.6%]). Lastly, par-
ticipants who had a history of stroke at baseline were excluded (n ¼
1669 [2.5%]) leaving a total of 58 712 participants (74.4%) included in 
the analyses (Fig. 1). 
2.2. Asthma 
Self-reported asthma status was ascertained using the HUNT baseline 
and the Lung Study questionnaires and stratified into three self-reported 
asthma groups ever asthma, active asthma and non-active asthma. Ever 
asthma was defined as those with an affirmative answer to “Have you 
ever had asthma?“. Active asthma was defined as those with an affir-
mative and not missing answer to all the following: “Have you ever had 
asthma?” (no missing), “Have you been diagnosed with asthma by a 
doctor?” (missing n ¼ 1395) and “In the past 12 months, have you used 
asthma medication?” (missing n ¼ 993). In addition, those who 
answered positively to the first ever asthma question but answered 
negatively to the third asthma medication question were classified as 
having non-active asthma (i.e. having asthma but not actively using 
asthma medication). No frequency or dosage has been recorded for the 
medication question, while those with missing answers were excluded 
from respective asthma group analyses. We regarded current asthma 
medication use, which requires doctor prescription, as a more reliable 
proxy for asthma status (i.e. passive or active) than asthma symptoms 
that can change over short period of time. 
2.3. Asthma control 
We matched the HUNT Lung study questions on asthma symptoms 
with asthma control assessment from the Global Initiative for Asthma 
(GINA) Global Strategy for Asthma Management and Prevention 
2016 [3] (Supplementary Table 3). Asthma control was categorized as 
controlled or not controlled asthma based on the following character-
istics: daytime symptoms (2 times per week or less or more than 2 
times/week, missing n ¼ 807), night awakenings (none or any, missing 
n ¼ 812), the need for reliever medication (2 times/week or less or more 
than 2 times/week, missing n ¼ 807) and limitation of activities (none or 
any, missing n ¼ 1085). Participants categorized in the controlled 
asthma group reported no such asthma characteristics and had no 
missing answers, while participants in the not controlled asthma group 
reported 1 or more characteristics. There were 1454 participants with 
missing on at least one of the asthma symptoms while 737 individuals 
had missing values for all the symptoms. 
2.4. Stroke ascertainment 
Incidence of ischemic stroke was ascertained by linking HUNT data 
with hospital electronic records from the two hospitals in Nord- 
Trøndelag County between 1995 and 2016. We used International Sta-
tistical Classification of Diseases and Related Health Problems, 9th 
Revision (ICD-9) codes 433 and 434 and 10th Revision (ICD-10) code 
I63 (all positions). Electronic medical records and diagnostic imaging of 
hospital admissions for stroke has been shown to have high sensitivity 
and positive predictive values [21,22]. 
2.5. Covariates 
A self-administrated questionnaire was used to assess participants’ 
smoking status (never, former and current), physical activity (inactive, 
low, medium and high), alcohol use (abstainers, light, moderate and 
heavy drinkers), education (<10, 10–12, >12 years) and medical history 
of common chronic diseases. Pack-years of smoking was calculated as: 
pack-years ¼ (number of cigarettes a day * years of smoking)/20. 
Comorbidities such as diabetes and COPD were self-reported at baseline. 
A detailed description of these covariates can be found elsewhere [5]. 
Body mass index (BMI) was categorized into 4 categories (under-
weight <18.5, normal 18.5–25, overweight 25–30, obese >30). Hy-
pertension was defined as systolic blood pressure �140 mmHg or 
diastolic blood pressure �90 mmHg or use of blood pressure lowering 
medication. Total cholesterol, high-density lipoprotein (HDL) and tri-
glycerides were measured in non-fasting fresh serum samples using 
Hitachi 911 Autoanalyzer (Hitachi) in HUNT2 and Architect cSystems 
ci8200 (Abott Diagnostic) in HUNT3. FEV1/FVC ratio was calculated 
from forced expiratory volume in 1 s (FEV1) and forced vital capacity 
(FVC) measurements during spirometry test using MasterScope Version 
4.1 (Jaeger) in a spirometry subsample of the HUNT Lung study (n ¼ 11 
622 within total sample and n ¼ 4385 among those with asthma). We 
used FEV1/FVC z-score of less than -1.64 to identify airway obstruction 
according to the Global Lung Function Initiative (GLI)-LLN method. This 
cut-off value has been shown to be clinically acceptable and is recom-
mended by The European Respiratory Society (ERS)/American Thoracic 
Society (ATS) [23,24]. C-reactive protein (CRP) was measured from 
serum samples taken during HUNT3 baseline medical visit using latex 
immunoassay methodology (Abbot). Information on self-reported 
asthma medication use was obtained from the Lung Study Question-
naire. Short acting beta2-agonists (SABA), long acting beta2-agonists 
(LABA) and inhaled corticosteroid (ICS) use was classified as 
non-current users or current users based on the regular use in the last 6 
months in HUNT2 and use in the last 12 months in HUNT3. 
2.6. Statistical analyses 
Baseline characteristics were presented as means and SDs for 
continuous variables and as numbers and percentages for categorical 
variables. We used Cox proportional hazard models to estimate hazard 
ratios (HRs) to assess the prospective association between asthma, 
asthma control and risk of stroke. Risk time was calculated from baseline 
until the examination at which stroke was first diagnosed, death, 
emigration or to the end of follow-up (31st December 2016) whichever 
came first. We used a time-varying approach which means that for those 
participants that attended both HUNT2 and HUNT3 examinations and 
did not have stroke before HUNT3, we used HUNT3 data to update 
asthma status and the status of the potential confounders (Fig. S2). 
A minimally adjusted model included sex, age and birth year cohort 
(birth calendar year in 5-year intervals) to account for the fact that the 
risk of stroke has decreased over time [25] (Model 1). In a fully adjusted 
model (Model 2), we controlled for traditional stroke risk factors 
including smoking status, physical activity, alcohol consumption, edu-
cation, BMI, total cholesterol/HDL ratio, hypertension and diabetes. We 
also evaluated effect modification by gender, smoking (history of 
smoking versus no smoking history) and age of asthma onset (child 
versus adult) by performing stratified analyses and by assessing inter-
action terms. Furthermore, we assessed possible mediating factors that 
could potentially contribute to the association between asthma and 
stroke. We compared HRs of the asthma groups and risk of stroke from 
Model 2 with and without inclusion of current beta2-agonists use (short 
and long acting), inhaled corticosteroids and C-reactive protein levels, 
all of which could act as a mediator of the association. 
We used attained age as the time scale in our analyses to account for 
age being a strong determinant of the disease in our study [26]. We 
tested for multicollinearity by assessing the correlation coefficient be-
tween variables in our models as well as performing variance inflation 
analysis (VIF) [27]. The proportionality of hazards was tested using 
log-log curves and the Schoenfeld test. Variables that showed evidence 
against proportionality in the formal test (p < 0.05) were treated as time 
varying covariates (smoking status and total cholesterol/HDL ratio). 
2.7. Sensitivity analysis 
In a sensitivity analysis, we repeated our analysis after adjusting for 
self-reported chronic comorbidities at baseline including cardiovascular 
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disease (acute myocardial infarction, heart failure and atrial fibrilla-
tion), hypo-, and –hyperthyroidism, rheumatoid arthritis, angina pec-
toris, fibromyalgia, ankylosing spondylitis, epilepsy and osteoporosis. 
Secondly, we also excluded participants who had been diagnosed with 
acute myocardial infarction, heart failure or atrial fibrillation at baseline 
or during follow-up and before stroke event. Thirdly, to minimize 
misclassification between COPD or heart failure and asthma we 
excluded participants with asthma who had self-reported chronic 
bronchitis or emphysema at baseline or had all of the following: post- 
bronchodilator FEV1/forced vital capacity Z score lower than -1.64, a 
history of smoking tobacco, and a diagnosis of asthma that occurred 
after the age of 40 years. We also adjusted for smoking pack-years after 
imputing missing data to assess potential residual confounding by 
smoking. Lastly, we performed multiple imputation by chained equa-
tions [28] for missing physical activity (n ¼ 9715) to assess any impact 
of missing data on the results. 
We performed the data analyses using Stata 15 for Windows 10 
(StataCorp). The study received ethics approval from the Regional 
Committee for Medical Research Ethics. All study participants gave 
informed written consent. 
3. Results 
A total of 58 712 individuals were used for the main analysis, out of 
which 2619 participants (4.5%) were diagnosed with ischemic stroke 
during a mean follow-up of 17.2 � 5.4 years contributing a total of 1 
008 091 person-years. The median age and stroke incidence were higher 
among males than females (46.4y. vs 44.5y. and 5.3% vs 3.8%). Of our 
study sample, 6485 adults (11.1%) reported asthma history at baseline 
while 2578 adults (4.4%) reported active asthma. Participants with 
asthma were more likely to be current smokers, have lower education, 
higher BMI and to have diabetes mellitus and COPD as well as higher 
CRP levels and lower FEV/FVC Z-Score than individuals without asthma 
(Table 1). In contrast, participants with non-active and controlled 
asthma were younger, less likely to be smokers, had higher education, 
lower BMI and lower prevalence of comorbidities than other asthma 
groups. In addition, participants with asthma and smoking history were 
more likely to have poorer asthma control, lower lung function and 
higher prevalence of comorbidities (Table S4). The prevalence of 
controlled asthma and not controlled asthma among participants with 
asthma was 2524 (38.9%) and 2507 (38.7%), respectively with 1454 
missing values (22.4%). 
3.1. Association of asthma and asthma control with stroke risk 
After adjustment for potential confounders (Model 2), there was no 
association between ever asthma and non-active asthma and risk of 
stroke (HR 1.07, 95% CI 0.95–1.22 and HR 0.95, 95% CI 0.76–1.20, 
respectively). Participants with active asthma showed some evidence for 
increased risk of developing stroke compared with those without asthma 
(HR 1.17, 95% CI 0.97–1.41) (Table 2). Similarly, we found a small 
increased risk of stroke among participants with not controlled asthma 
compared to controlled asthma (HR 1.34, 95% CI 1.03–1.73). 
3.2. Other analyses 
Among 6485 participants with asthma, 2270 (35.0%) and 1394 in-
dividuals (21.5%) currently used beta2-agonists and ICS with 794 
(12.2%) and 1394 (21.5%) missing values, respectively. Adjustment for 
beta2-agonists or ICS use increased the absolute relative risk for stroke 
by 29% in the active asthma group and 18% and 5%, respectively, in not 
controlled asthma group (Table 3). HRs did not change after adjustment 
for hsCRP levels (results not shown). 
The relative risk for stroke was higher among adults with history of 
smoking in ever and active asthma groups (HR 1.17, 95% CI 1.01–1.35 
and HR 1.31, 95% CI 1.06–1.62, respectively with p for interaction 
Table 1 
Baseline characteristics of asthma groups in 58 712 participants at baseline.  
Characteristic No 
asthma 
(n ¼ 52 
227) 
Ever 
asthma 
(n ¼
6485) 
Active 
asthma 
(n ¼
2578) 
Controlled 
(n ¼ 2524) 
Not 
controlled 
(n ¼ 2507) 
Female 27 543 
(53%) 
3538 
(55%) 
1480 
(57%) 
1413 (56%) 1362 
(54%) 
Smoking 
Never 23 278 
(45%) 
2467 
(38%) 
894 
(35%) 
1052 (42%) 825 (33%) 
Former 13 970 
(27%) 
1948 
(30%) 
879 
(34%) 
729 (29%) 853 (34%) 
Current 14 979 
(29%) 
2047 
(32%) 
805 
(31%) 
743 (29%) 830 (33%) 
Pack-Yearsa 6.63 �
10.3 
8.4 �
11.9 
9.5 �
12.7 
6.8 � 10.6 10.6 � 13.5 
Physical activity 
Inactive 9753 
(19%) 
1300 
(20%) 
564 
(22%) 
431 (17%) 601 (24%) 
Low 14 959 
(29%) 
1799 
(28%) 
735 
(28%) 
704 (28%) 725 (29%) 
Medium 21 422 
(41%) 
2554 
(39%) 
995 
(39%) 
1041 (41%) 936 (37%) 
High 6093 
(12%) 
809 
(13%) 
284 
(11%) 
348 (14%) 245 (10%) 
Alcohol use 
Abstainers 17 138 
(33%) 
2232 
(35%) 
940 
(36%) 
770 (31%) 970 (39%) 
Light 27 055 
(52%) 
3280 
(51%) 
1275 
(50%) 
1369 (54%) 1195 
(47%) 
Moderate/ 
Heavy 
8034 
(15%) 
950 
(14%) 
363 
(14%) 
385 (15%) 342 (14%) 
Education 
<10y 15 445 
(30%) 
2055 
(32%) 
915 
(35%) 
657 (26%) 950 (38%) 
10-12y 24 238 
(46%) 
3030 
(47%) 
1179 
(46%) 
1252 (50%) 1129 
(45%) 
>12y 12 544 
(24%) 
1377 
(21%) 
484 
(19%) 
615 (24%) 428 (17%) 
BMI 
Under/ 
Normal 
21 879 
(42%) 
2372 
(37%) 
900 
(35%) 
940 (37%) 863 (35%) 
Over 22 315 
(43%) 
2698 
(42%) 
1066 
(41%) 
1084 (43%) 1031 
(41%) 
Obese 8033 
(15%) 
1392 
(21%) 
612 
(24%) 
500 (20%) 588 (24%) 
Asthma Medicationb 
Beta2-agonist 
use 
– 2114 
(37%) 
1758 
(68%) 
464 (18%) 1616 
(65%) 
ICS use – 1234 
(24%) 
1626 
(43%) 
523 (21%) 1335 
(53%) 
Asthma Symptoms 
Daytime 
Symptoms 
– 1411 
(25%) 
929 
(36%) 
– 1412 
(57%) 
Night 
Awakenings 
– 905 
(16%) 
648 
(25%) 
– 906 (37%) 
Limitations 
activities 
– 464 
(8.6%) 
352 
(14%) 
– 464 (21%) 
Diabetes 
Mellitus 
1168 
(2.2%) 
200 
(3.1%) 
87 
(3.4%) 
57 (2.3%) 101 (4.0%) 
Hypertension 19 588 
(38%) 
2509 
(39%) 
1105 
(43%) 
814 (32%) 1139 
(45%) 
Self-reported 
COPD 
826 
(1.6%) 
1320 
(20%) 
781 
(30%) 
397 (16%) 767 (31%) 
Asthma 
Duration (y) 
– 22.2 �
18.5 
18.6 �
15.9 
24.8 � 16.6 19.6 � 16.9 
Asthma onset 
(age) 
– 26.4 �
21.4 
32.4 �
20.8 
21.4 � 19.6 31.5 � 21.7 
FEV1/FVC Z 
scorec 
-0.39 �
0.98 
-0.65 �
1.08 
-1.09 �
1.30 
-0.60 �
1.00 
-1.19 �
1.37 
Age (y) 46.5 �
15.9 
46.3 �
16.0 
48.5 �
15.8 
43.8 � 14.6 49.7 � 16.3 
Total C:HDL 4.5 �
1.6 
4.51 �
1.56 
4.5 �
1.5 
4.5 � 1.5 4.6 � 1.6 
Triglycerides 
(mmol/L) 
1.7 �
1.1 
1.75 �
1.12 
1.8 �
1.1 
1.7 � 1.1 1.8 � 1.2 
(continued on next page) 
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between asthma status and smoking history <0.100) as well as not 
controlled asthma group (1.48, 95% CI 1.10–2.00, p for interaction ¼
0.387) (Table 4). The risk of stroke was absent in participants with no 
smoking history in all asthma groups. Gender stratification revealed a 
stronger relative risk of stroke among males than females within the 
active asthma group (HR 1.31, 95% CI 1.03–1.66 p for interaction ¼
0.140) and the not controlled asthma group (HR 1.55, 95% CI 
1.12–2.16, p for interaction ¼ 0.216) (Table 4). Lastly, we found no 
strong changes in HRs or evidence for interaction between asthma 
groups and age of onset (child vs adult, p for interaction >0.200, missing 
age of asthma onset n ¼ 1571) (results not shown). 
3.3. Sensitivity analyses 
The results for asthma and asthma control remained consistent after 
adjusting for self-reported comorbidities at baseline (n ¼ 14 493), 
excluding participants with other prevalent and incident CVD events 
before censoring (n ¼ 4912) (Table S6) or imputing missing data on 
physical activity (n ¼ 9715) and adjusting for it (Table S6). Similarly, 
HRs did not change after excluding participants with asthma who either 
had self-reported COPD at baseline (n ¼ 1320) or had all of the following 
(n for presence of all characteristics ¼ 202): post-bronchodilator FEV1/ 
forced vital capacity Z score lower than -1.64 (n ¼ 803), a history of 
smoking tobacco (n ¼ 4012), and a diagnosis of asthma that occurred 
after the age of 40 years (n ¼ 941), with a total exclusion of 1425 par-
ticipants. Excluding COPD cases (n ¼ 1023) with the same criteria 
among those with history of smoking, increased HR in the active asthma 
group (HR 1.45, 95% CI 1.09–1.93) and the not controlled asthma group 
(HR 1.69, 95% CI 1.17–2.45) compared to the main analysis (HR 1.34, 
95% CI 1.03–1.73 and HR 1.43, 95% CI 1.07–1.91) (Table S7). Lastly, 
adjusting for smoking pack-years among those with history of smoking 
did not change HRs. 
4. Discussion 
The results of this large prospective study show that participants 
with self-reported history of asthma and current asthma medication use 
Table 1 (continued ) 
Characteristic No 
asthma 
(n ¼ 52 
227) 
Ever 
asthma 
(n ¼
6485) 
Active 
asthma 
(n ¼
2578) 
Controlled 
(n ¼ 2524) 
Not 
controlled 
(n ¼ 2507) 
C-reactive 
protein (μg/ 
mL)d 
2.6 �
5.6 
3.19 �
6.37 
3.3 �
6.3 
2.8 � 5.4 3.7 � 7.4 
Values are mean � SD or n (%). 
Abbreviations: BMI, body mass index; Total C/HDL, total cholesterol to high 
density lipoprotein ratio. 
a Calculated as: pack-years ¼ (number of cigarettes a day * years of smoking)/ 
20 (n ¼ 55 542). 
b Current use defined as use in the last 6 months at HUNT2 baseline for ICS 
and last month for beta2-agonist and last 12 months at HUNT3 baseline for both 
medications. 
c Force expiratory volume/Forced vital capacity Z-score based on Global Lung 
Function Initiative (GLI)-LLN method measured in small subsample (n ¼ 11 
622). 
d CRP measured in HUNT3 and a small subsample of HUNT2 cohort (total n ¼
41 835). 
Table 2 
Associations between asthma, asthma control and the risk of stroke during 17.2 years of follow-up.   
N No. of cases (%) Unadjusted Model 1 Model 2 
Asthma Status 
No asthma 52 227 2317 (4.4%) Reference Reference Reference 
Ever asthma 6485 302 (4.7%) 1.10 (0.97–1.25) 1.10 (0.97–1.25) 1.07 (0.95–1.22) 
Non-active 2565 88 (3.7%) 0.98 (0.78–1.23) 0.97 (0.77–1.22) 0.95 (0.76–1.20) 
Active asthma 2578 144 (5.6%) 1.20 (1.00–1.45)* 1.21 (1.00–1.45)* 1.17 (0.97–1.41) 
Asthma control 
Controlled 2524 88 (3.5%) Reference Reference Reference 
Not controlled 2507 142 (5.7%) 1.39 (1.10–1.76) 1.39 (1.08–1.79) 1.34 (1.03–1.73) 
Hazard ratios and 95% confidence intervals were derived from Cox proportional hazards models. 
Model 1 adjusted for age, birth year cohort and sex. 
Model 2 adjusted for age, birth year cohort, sex, BMI, smoking status, alcohol use, education level, total cholesterol/HDL ratio, hypertension and diabetes mellitus. 
*p value ¼ 0.051 and 0.048 for unadjusted and model 1, respectively. 
Table 3 
Mediation analysis for the associations between asthma, asthma control and the risk of stroke.   
Beta2-Agonist use (n ¼ 57 918)a ICS Use (n ¼ 57 318)a 
Model 2 adjusted HRb Model 2 þ Mediator adjusted HRc Change (%)f Model 2 adjusted HRd Model 2 þ Mediator adjusted HRe Change (%)f 
Asthma Status 
No asthma Reference Reference  Reference Reference  
Ever asthma 1.00 (0.87–1.14) 1.00 (0.84–1.18) 0 1.10 (0.94–1.28) 1.15 (0.94–1.41) 5 
Non-active asthma – – – – – – 
Active asthma 1.16 (0.95–1.40) 1.45 (1.06–1.97) 29 1.13 (0.93–1.38) 1.42 (1.02–1.99) 29 
Asthma Control 
Controlled Reference Reference  Reference Reference  
Not controlled 1.32 (1.03–1.71) 1.50 (1.07–2.10) 18 1.28 (0.97–1.68) 1.33 (0.96–1.85) 5  
a Beta2-agonist users n ¼ 2270 (35.0%) and missing n ¼ 794 (12.2%) among adults with asthma; ICS users n ¼ 1241 (19.1%) and missing n ¼ 1394 (21.5%) among 
adults with asthma. Current use defined as use in the last 6 months at HUNT2 baseline for ICS and last month for beta2-agonist and last 12 months at HUNT3 baseline 
for both medications. 
b Adjusted for Model 2; participants with missing current beta2-agonist medication use information excluded. 
c Adjusted for model 2 and current beta2-agonist use. 
d Adjusted for Model 2; participants with missing current ICS medication use information excluded. 
e Adjusted for model 2 and current ICS use. 
f Mediation was assessed as the absolute change between model 2 only adjusted HR and model 2 þ mediator adjusted HR. 
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and a history of smoking or presence of asthma symptoms have a modest 
increased risk of stroke. The association between asthma and stroke was 
absent among lifetime non-smokers suggesting the asthma-stroke asso-
ciation may in part be due to smoking or potential misclassification of 
COPD as asthma. In addition, associations were stronger in males than 
females, indicating modifying effect by gender. 
Several previous studies have investigated the association between 
asthma and stroke [13–18]. A Taiwanese nationwide prospective study 
found a modest higher risk of stroke in a cohort of adults diagnosed with 
adult-onset asthma and a history of asthma medication use (HR 1.37, 
95% CI: 1.27–1.48) compared to those without asthma [17]. Another 
large prospective study of 2 matched cohorts using an insurance data-
base found a similar modest increased risk of stroke in adults with 
asthma (HR 1.20, 95% CI: 1.15–1.25) [16]. However, a recent large 
Korean case-control study did not find increased ischemic stroke risk 
among participants with asthma (HR 0.91, 95% CI 0.86–0.95) [18]. 
These studies did not address the possible misclassification of COPD as 
asthma, some did not have information on smoking status and asthma 
symptoms and some of the important potential confounders such as 
alcohol use, education and physical activity were missing. 
In line with our study, a large prospective study found higher stroke 
mortality among current smokers (HR 1.97, 95% CI: 1.20–3.23) than 
non or ex-smokers (HR 0.87, 95% CI: 0.53–1.43) within the active 
asthma group [14]. Similarly, stroke risk slightly attenuated in partici-
pants with asthma after excluding lifetime smokers in a community 
cohort (HR 1.55, 95% CI:0.95–2.52 vs HR 1.26, 95% CI: 0.68–2.33) [15] 
and in Copenhagen prospective study [29]. We found evidence for 
interaction between smoking and asthma status with increased risk of 
stroke in adults with active and not controlled asthma and a history of 
smoking but not in lifetime non-smokers. 
The prevalence of tobacco smoking is high in individuals with 
asthma and it is a significant risk factor for both stroke and asthma [10]. 
Active cigarette smoking interacts with asthma which causes more se-
vere symptoms and frequent asthma exacerbations, accelerated decline 
in lung function, and adverse effects on clinical, prognostic and thera-
peutic outcomes [12,30]. It has been reported that impaired lung 
function is strongly associated with mortality and CVD risk including 
stroke [31,32]. In addition, participants with asthma and no smoking 
history reported no excess CVD risk compared to non-smokers without 
asthma within a Danish cohort [29]. In line with these findings, we 
observed more frequent asthma symptoms and medication use, poorer 
lung function and higher prevalence of comorbidities in smokers with 
asthma than non-smokers with asthma in our study. Also, excluding 
individuals with history of smoking diminished stroke risk in those 
reporting recent asthma symptoms. Therefore, it is highly likely that 
higher risk of stroke arises from tobacco smoking which combined with 
the presence of asthma may lead to multiple adverse outcomes and 
poorer prognosis. This enforces the idea that quitting smoking should be 
highly encouraged in those with asthma. 
Obstructive lung diseases are characterized by airflow limitation and 
include both asthma and chronic obstructive pulmonary disease 
(COPD). In Norway, COPD was often called asthma at the time of 
HUNT2 study and we found that 35% of those with asthma and current 
smoking had self-reported COPD in our study. COPD is most prevalent 
among smokers and have been associated with increased risk of stroke 
[11]. In addition, asthma and COPD, although distinctive, share many 
similar features and often co-exists together termed as asthma-COPD 
overlap syndrome [33]. Those with asthma-COPD overlap are more 
likely to have worse respiratory symptoms, poorer quality of life, 
increased exacerbations and hospital admissions than those with asthma 
alone [33,34]. Therefore, we considered that the excess stroke risk in 
individuals with asthma and smoking may be partly due to 
asthma-COPD overlap or misclassification of COPD as asthma in 
smokers. In addition, previous study has shown that majority of the 
stroke risk in COPD patients is attributed to the history of smoking [35]. 
Although, in our study stroke risk slightly increased after excluding 
participants with self-reported COPD and COPD characteristics in 
smokers, the likelihood of misclassification remains. 
In addition, we found higher risk of stroke in the not controlled 
asthma group compared to the controlled asthma group, characterized 
by the presence of at least one asthma symptom at baseline. In line with 
our findings, a previous prospective study found that participants 
reporting attacks of wheezing and shortness of breath had a greater risk 
for stroke compared to participants with asthma, but without these 
symptoms [15]. Poor asthma symptom control could be as a result of 
persistent smoking and suboptimal asthma treatment. Asthma medica-
tion, ICS with or without beta2-agonists (SABA or LABA), is the first line 
of approach for asthma control [36]. It has been reported that a good 
adherence to a combination of ICS with LABA or SABA treatment results 
in a better long-term asthma control and less hospital admissions and 
exacerbations and improved lung function [37–39]. 
On the other hand, an American prospective study found an 
increased stroke risk in asthma medication users, but not in non-users at 
baseline and during follow-up [16]. Beta2-agonists, the most common 
asthma medication, is considered to be a significant risk factor for 
incident atrial fibrillation [4], which in turn is associated with 4-fold 
increased risk of stroke [6]. However, beta2-agonists have also been 
shown to improve lung function and reduce symptoms eliminating 
night-time awakenings and exercise-induced asthma as well as 
improving quality of life [40–42]. Thus, the higher stroke risk in 
medication users may reflect confounding by indication, as medication 
is prescribed during times of asthma exacerbations and frequent symp-
toms. In our study, adjustment for current beta2-agonist use slightly 
increased the risk of stroke in active asthma and uncontrolled asthma 
groups, indicating a potentially protective effect. In addition, including 
asthmatics with symptoms of asthma in the past 12 months but not 
taking asthma medication to active asthma group did not change the 
results. 
Table 4 
Stratification by smoking history and gender in the associations between asthma, asthma control and the risk of stroke.  
Categories Smoking History P value* Gender P value* 
Never smokers (n ¼ 25 751) Ever smokersa (n ¼ 32 961) Female (n ¼ 31 081) Male (n ¼ 27 631) 
Asthma Status 
No asthma Reference Reference  Reference Reference  
Ever asthma 0.88 (0.69–1.11) 1.17 (1.01–1.35) 0.052 1.00 (0.83–1.22) 1.13 (0.96–1.33) 0.341 
Non-active asthma 0.86 (0.58–1.30) 0.99 (0.75–1.31) 0.595 0.96 (0.67–1.38) 0.95 (0.70–1.29) 0.953 
Active asthma 0.87 (0.59–1.30) 1.31 (1.06–1.62) 0.098 1.00 (0.74–1.35) 1.31 (1.03–1.66) 0.140 
Asthma Control 
Controlled Reference Reference  Reference Reference  
Not controlled 1.02 (0.61–1.70) 1.48 (1.10–2.00) 0.387 1.05 (0.69–1.60) 1.555 (1.12–2.16) 0.216 
Hazard ratios and 95% confidence intervals were derived from Cox proportional hazards models. 
Adjusted for age, birth year cohort, sex, BMI, smoking status, alcohol use, education level, total cholesterol/HDL ratio, hypertension and diabetes mellitus. 
*P for interaction between asthma status and smoking history or gender. 
a Ever smokers include former and current smokers. 
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In our study, we observed higher relative risk for stroke among males 
than females within the active and not controlled asthma groups. Only 
one previous study detected gender differences, which found that fe-
males with adult-onset asthma had higher carotid intima media thick-
ness [43] and relative risk for stroke than males in crude analysis [13]. 
However, the association was found in crude analysis and study had a 
very small sample size (stroke cases n ¼ 19). The effect of hormones 
could alter the association between asthma and stroke due to oestrogen 
levels exerting modifying effects on inflammatory response and poten-
tial protecting against vascular inflammation and endothelial damage in 
pre-menopausal women in our study (median age of women in our study 
was 44.0y.) [44]. Also, in our study males had higher median age and 
overall incidence of stroke than females whereas it has been previously 
reported that the median age of first stroke is 4 years lower in males than 
females [45]. 
Other potential mechanism underlying the possible association be-
tween asthma and risk of stroke is a higher atrial fibrillation risk among 
adults with asthma, and especially active asthma [5,46]. Arrhythmias 
have been found to be a significant risk factors for stroke in observa-
tional studies [6,47]. Furthermore, it is speculated that asthma may 
predispose to atherosclerosis through pathophysiologic pathways linked 
to the chronic inflammatory response [48]. However, we did not find 
any mediating effect of hsCRP, an inflammatory biomarker, in the as-
sociation between asthma and stroke. 
Our study had several strengths. First, we utilized data from a large 
cohort with a long follow-up, extensive information on a wide range of 
confounders and on asthma medication use was available, the study also 
had a high participation rate and carefully reviewed hospital and reg-
ister information. All variables including asthma, asthma control and 
confounders were measured both in HUNT2 and HUNT3 and updated in 
the analysis for most of the participants allowing us to take into account 
potential changes in participants’ lifestyle habits or exposure status over 
time. 
One of the limitations is that the observational nature of the data 
could have resulted in residual confounding. However, to influence our 
results, a potential unmeasured confounder would have to be strongly 
associated with both asthma and stroke and be unrelated to the con-
founders already included in our models. 
We did not have clinical measures for asthma or COPD and had to 
rely on the self-reported questionnaires, which could have resulted in 
potentially non-differential misclassification of the exposure. However, 
it has been reported that questions on ever asthma and physician diag-
nosed asthma have high specificity (>90%) [49] and high positive 
predictive value that give prevalence estimates close to those obtained 
by clinical judgement [50]. In Norway, COPD was often labelled as 
asthma by the doctors up until the early 2000s, thus misclassification of 
COPD as asthma is likely. To partly address this, we excluded partici-
pants with self-reported COPD and with COPD characteristics within the 
asthma groups. However, spirometry data had high missing (n ¼ 2100 
among those with asthma) and self-reported COPD would not address 
substantial under-diagnosis. 
The response rate was 69% in HUNT2 (n ¼ 65 299), 54% in HUNT3 
(n ¼ 50 807), and 68% in the Lung Study (n ¼ 16 115), which could have 
introduced selection bias. However, non-respondent studies were per-
formed for HUNT2 and HUNT3 [19,51]. The main reasons for not 
attending the health survey were lack of time or having moved out of the 
county, while those in age group of 70 þ commonly reported to have 
regular follow-up by a doctor or hospital and therefore did not need to 
attend the health survey in HUNT2 [52]. There were no difference for 
respiratory symptoms or asthma, while stroke was slightly more prev-
alent in non-responders in HUNT3 [51]. 
In summary, we observed increased stroke risk among adults with 
presence of asthma symptoms and those with asthma and a history of 
smoking with higher relative risk in male gender. Asthma and smoking 
interaction suggest poorer prognosis in smokers with asthma than non- 
smokers. The findings highlight the importance of smoking cessation in 
those with asthma. Future studies should clarify the difference in risks 
and mechanisms between different phenotypes of asthma. 
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